High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F
To study the clinical features of patients with autoantibodies to centromere protein CENP-F and the frequency of CENP-F autoantibodies in patients with various diseases. Retrospective clinical and serologic study. Thirty-six patients with anti-CENP-F were identified by a characteristic pattern of in...
Gespeichert in:
| Veröffentlicht in: | Clinical and investigative medicine 1997-10, Vol.20 (5), p.308-319 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 319 |
|---|---|
| container_issue | 5 |
| container_start_page | 308 |
| container_title | Clinical and investigative medicine |
| container_volume | 20 |
| creator | RATTNER, J. B REES, J WHITEHEAD, C. M CASIANO, C. A TAN, E. M HUMBEL, R. L CONRAD, K FRITZLER, M. J |
| description | To study the clinical features of patients with autoantibodies to centromere protein CENP-F and the frequency of CENP-F autoantibodies in patients with various diseases.
Retrospective clinical and serologic study.
Thirty-six patients with anti-CENP-F were identified by a characteristic pattern of indirect immunofluorescence (IIF) on HEp-2 cells. Fifty patients with melanoma, 50 with breast cancer, 10 with lung cancer, 354 with systemic sclerosis, 120 with systemic lupus erythematosus and 50 with rheumatoid arthritis were also studied. Recombinant proteins were produced from 5 CENP-F cDNA clones representing amino acids 2192-3317 (p-F1), 5561-7126 (p-F2), 5892-6883 (p-F3), 7538-10,116 (p-F4) and 9242-10,096 (p-F5). The presence of CENP-F antigen was studied in a breast carcinoma cell line, cryosections of breast carcinoma, normal breast tissue and tonsils.
Twenty-two of 36 patients with CENP-F antibodies had neoplasms; breast (9/22) and lung (5/22) cancer were the most common diagnoses. Thirty-three sera were available for further study; when tested for reactivity to the recombinant peptides, the sera of 21 of 21 patients with neoplasms and 5 of 12 patients with other diseases bound the C-terminal p-F4 peptide. When the terminal third of the p-F4 peptide (p-F5) was studied, a significant difference in pattern of reactivity was not detected. By comparison, the frequency of reactivity with peptides representing other domains of CENP-F was less than that with p-F4 (p-F2 > p-F3 > p-F1). CENP-F autoantibodies were not found in any of the control sera from patients with systemic lupus erythematosus, rheumatoid arthritis or systemic sclerosis or in unselected sera from various malignancies. CENP-F antigens were identified in breast carcinoma tissue but were rarely observed in normal tissues.
A high proportion of individuals with CENP-F antibodies have neoplasia, and there is a bias among their sera for reactivity with determinants in the carboxy terminal domain of CENP-F. CENP-F antigens appear to be highly expressed in malignant tissues. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79341151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19472186</sourcerecordid><originalsourceid>FETCH-LOGICAL-p262t-cf3e09a96f1109116d2cfadbf2c9d9b2f7f9bfafe6bdc3a39d41ed7dcc7cc4843</originalsourceid><addsrcrecordid>eNpdkE1LxDAQhoMo61r9CUIQ8VZoPpo2R1l2XWFRDwp7K2k-3CxtU5MU2X9vwOLBuczhfWbmfecMLBGt6xyTkpyDZYFolfOy3l-CqxCORVHgkvEFWHBCGCvZEuy39vMAjddfkx7kCToDB-3GTgQroB3gKKLVQwzw28YDFFN0Yoi2dcrqAKODMone9dprOHoXdRpZrV_e8s01uDCiC_pm7hn42KzfV9t89_r0vHrc5SNmOObSEF1wwZlBqOAIMYWlEao1WHLFW2wqw1sjjGatkkQQrijSqlJSVlLSmpIMPPzuTedThhCb3gapu06kHFNoKk4oQiVK4N0_8OgmPyRvDeKM4pKkysDtDE1tr1UzetsLf2rmfyX9ftZFkKIzXgzShj8MF5RSxMgPNr114w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196425333</pqid></control><display><type>article</type><title>High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>RATTNER, J. B ; REES, J ; WHITEHEAD, C. M ; CASIANO, C. A ; TAN, E. M ; HUMBEL, R. L ; CONRAD, K ; FRITZLER, M. J</creator><creatorcontrib>RATTNER, J. B ; REES, J ; WHITEHEAD, C. M ; CASIANO, C. A ; TAN, E. M ; HUMBEL, R. L ; CONRAD, K ; FRITZLER, M. J</creatorcontrib><description>To study the clinical features of patients with autoantibodies to centromere protein CENP-F and the frequency of CENP-F autoantibodies in patients with various diseases.
Retrospective clinical and serologic study.
Thirty-six patients with anti-CENP-F were identified by a characteristic pattern of indirect immunofluorescence (IIF) on HEp-2 cells. Fifty patients with melanoma, 50 with breast cancer, 10 with lung cancer, 354 with systemic sclerosis, 120 with systemic lupus erythematosus and 50 with rheumatoid arthritis were also studied. Recombinant proteins were produced from 5 CENP-F cDNA clones representing amino acids 2192-3317 (p-F1), 5561-7126 (p-F2), 5892-6883 (p-F3), 7538-10,116 (p-F4) and 9242-10,096 (p-F5). The presence of CENP-F antigen was studied in a breast carcinoma cell line, cryosections of breast carcinoma, normal breast tissue and tonsils.
Twenty-two of 36 patients with CENP-F antibodies had neoplasms; breast (9/22) and lung (5/22) cancer were the most common diagnoses. Thirty-three sera were available for further study; when tested for reactivity to the recombinant peptides, the sera of 21 of 21 patients with neoplasms and 5 of 12 patients with other diseases bound the C-terminal p-F4 peptide. When the terminal third of the p-F4 peptide (p-F5) was studied, a significant difference in pattern of reactivity was not detected. By comparison, the frequency of reactivity with peptides representing other domains of CENP-F was less than that with p-F4 (p-F2 > p-F3 > p-F1). CENP-F autoantibodies were not found in any of the control sera from patients with systemic lupus erythematosus, rheumatoid arthritis or systemic sclerosis or in unselected sera from various malignancies. CENP-F antigens were identified in breast carcinoma tissue but were rarely observed in normal tissues.
A high proportion of individuals with CENP-F antibodies have neoplasia, and there is a bias among their sera for reactivity with determinants in the carboxy terminal domain of CENP-F. CENP-F antigens appear to be highly expressed in malignant tissues.</description><identifier>ISSN: 0147-958X</identifier><identifier>EISSN: 1488-2353</identifier><identifier>PMID: 9336656</identifier><identifier>CODEN: CNVMDL</identifier><language>eng</language><publisher>Toronto, ON: Canadian Medical Association</publisher><subject>Adult ; Aged ; Autoantibodies - blood ; Autoantigens - immunology ; Biological and medical sciences ; Breast Neoplasms - immunology ; Carcinoma, Small Cell - immunology ; Centromere - immunology ; Chromosomal Proteins, Non-Histone - immunology ; Female ; Fluorescent Antibody Technique, Indirect ; Humans ; Immunology ; Investigative techniques, diagnostic techniques (general aspects) ; Lung Neoplasms - immunology ; Male ; Medical sciences ; Melanoma - immunology ; Microfilament Proteins ; Middle Aged ; Miscellaneous. Technology ; Neoplasms - immunology ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Proteins ; Retrospective Studies ; Rheumatic Diseases - immunology</subject><ispartof>Clinical and investigative medicine, 1997-10, Vol.20 (5), p.308-319</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright Canadian Medical Association Oct 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2044416$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9336656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RATTNER, J. B</creatorcontrib><creatorcontrib>REES, J</creatorcontrib><creatorcontrib>WHITEHEAD, C. M</creatorcontrib><creatorcontrib>CASIANO, C. A</creatorcontrib><creatorcontrib>TAN, E. M</creatorcontrib><creatorcontrib>HUMBEL, R. L</creatorcontrib><creatorcontrib>CONRAD, K</creatorcontrib><creatorcontrib>FRITZLER, M. J</creatorcontrib><title>High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F</title><title>Clinical and investigative medicine</title><addtitle>Clin Invest Med</addtitle><description>To study the clinical features of patients with autoantibodies to centromere protein CENP-F and the frequency of CENP-F autoantibodies in patients with various diseases.
Retrospective clinical and serologic study.
Thirty-six patients with anti-CENP-F were identified by a characteristic pattern of indirect immunofluorescence (IIF) on HEp-2 cells. Fifty patients with melanoma, 50 with breast cancer, 10 with lung cancer, 354 with systemic sclerosis, 120 with systemic lupus erythematosus and 50 with rheumatoid arthritis were also studied. Recombinant proteins were produced from 5 CENP-F cDNA clones representing amino acids 2192-3317 (p-F1), 5561-7126 (p-F2), 5892-6883 (p-F3), 7538-10,116 (p-F4) and 9242-10,096 (p-F5). The presence of CENP-F antigen was studied in a breast carcinoma cell line, cryosections of breast carcinoma, normal breast tissue and tonsils.
Twenty-two of 36 patients with CENP-F antibodies had neoplasms; breast (9/22) and lung (5/22) cancer were the most common diagnoses. Thirty-three sera were available for further study; when tested for reactivity to the recombinant peptides, the sera of 21 of 21 patients with neoplasms and 5 of 12 patients with other diseases bound the C-terminal p-F4 peptide. When the terminal third of the p-F4 peptide (p-F5) was studied, a significant difference in pattern of reactivity was not detected. By comparison, the frequency of reactivity with peptides representing other domains of CENP-F was less than that with p-F4 (p-F2 > p-F3 > p-F1). CENP-F autoantibodies were not found in any of the control sera from patients with systemic lupus erythematosus, rheumatoid arthritis or systemic sclerosis or in unselected sera from various malignancies. CENP-F antigens were identified in breast carcinoma tissue but were rarely observed in normal tissues.
A high proportion of individuals with CENP-F antibodies have neoplasia, and there is a bias among their sera for reactivity with determinants in the carboxy terminal domain of CENP-F. CENP-F antigens appear to be highly expressed in malignant tissues.</description><subject>Adult</subject><subject>Aged</subject><subject>Autoantibodies - blood</subject><subject>Autoantigens - immunology</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - immunology</subject><subject>Carcinoma, Small Cell - immunology</subject><subject>Centromere - immunology</subject><subject>Chromosomal Proteins, Non-Histone - immunology</subject><subject>Female</subject><subject>Fluorescent Antibody Technique, Indirect</subject><subject>Humans</subject><subject>Immunology</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Lung Neoplasms - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma - immunology</subject><subject>Microfilament Proteins</subject><subject>Middle Aged</subject><subject>Miscellaneous. Technology</subject><subject>Neoplasms - immunology</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Proteins</subject><subject>Retrospective Studies</subject><subject>Rheumatic Diseases - immunology</subject><issn>0147-958X</issn><issn>1488-2353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkE1LxDAQhoMo61r9CUIQ8VZoPpo2R1l2XWFRDwp7K2k-3CxtU5MU2X9vwOLBuczhfWbmfecMLBGt6xyTkpyDZYFolfOy3l-CqxCORVHgkvEFWHBCGCvZEuy39vMAjddfkx7kCToDB-3GTgQroB3gKKLVQwzw28YDFFN0Yoi2dcrqAKODMone9dprOHoXdRpZrV_e8s01uDCiC_pm7hn42KzfV9t89_r0vHrc5SNmOObSEF1wwZlBqOAIMYWlEao1WHLFW2wqw1sjjGatkkQQrijSqlJSVlLSmpIMPPzuTedThhCb3gapu06kHFNoKk4oQiVK4N0_8OgmPyRvDeKM4pKkysDtDE1tr1UzetsLf2rmfyX9ftZFkKIzXgzShj8MF5RSxMgPNr114w</recordid><startdate>19971001</startdate><enddate>19971001</enddate><creator>RATTNER, J. B</creator><creator>REES, J</creator><creator>WHITEHEAD, C. M</creator><creator>CASIANO, C. A</creator><creator>TAN, E. M</creator><creator>HUMBEL, R. L</creator><creator>CONRAD, K</creator><creator>FRITZLER, M. J</creator><general>Canadian Medical Association</general><general>Canadian Society for Clinical Investigation</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M3G</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19971001</creationdate><title>High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F</title><author>RATTNER, J. B ; REES, J ; WHITEHEAD, C. M ; CASIANO, C. A ; TAN, E. M ; HUMBEL, R. L ; CONRAD, K ; FRITZLER, M. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p262t-cf3e09a96f1109116d2cfadbf2c9d9b2f7f9bfafe6bdc3a39d41ed7dcc7cc4843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Autoantibodies - blood</topic><topic>Autoantigens - immunology</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - immunology</topic><topic>Carcinoma, Small Cell - immunology</topic><topic>Centromere - immunology</topic><topic>Chromosomal Proteins, Non-Histone - immunology</topic><topic>Female</topic><topic>Fluorescent Antibody Technique, Indirect</topic><topic>Humans</topic><topic>Immunology</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Lung Neoplasms - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma - immunology</topic><topic>Microfilament Proteins</topic><topic>Middle Aged</topic><topic>Miscellaneous. Technology</topic><topic>Neoplasms - immunology</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Proteins</topic><topic>Retrospective Studies</topic><topic>Rheumatic Diseases - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RATTNER, J. B</creatorcontrib><creatorcontrib>REES, J</creatorcontrib><creatorcontrib>WHITEHEAD, C. M</creatorcontrib><creatorcontrib>CASIANO, C. A</creatorcontrib><creatorcontrib>TAN, E. M</creatorcontrib><creatorcontrib>HUMBEL, R. L</creatorcontrib><creatorcontrib>CONRAD, K</creatorcontrib><creatorcontrib>FRITZLER, M. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>CBCA Reference & Current Events</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and investigative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RATTNER, J. B</au><au>REES, J</au><au>WHITEHEAD, C. M</au><au>CASIANO, C. A</au><au>TAN, E. M</au><au>HUMBEL, R. L</au><au>CONRAD, K</au><au>FRITZLER, M. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F</atitle><jtitle>Clinical and investigative medicine</jtitle><addtitle>Clin Invest Med</addtitle><date>1997-10-01</date><risdate>1997</risdate><volume>20</volume><issue>5</issue><spage>308</spage><epage>319</epage><pages>308-319</pages><issn>0147-958X</issn><eissn>1488-2353</eissn><coden>CNVMDL</coden><abstract>To study the clinical features of patients with autoantibodies to centromere protein CENP-F and the frequency of CENP-F autoantibodies in patients with various diseases.
Retrospective clinical and serologic study.
Thirty-six patients with anti-CENP-F were identified by a characteristic pattern of indirect immunofluorescence (IIF) on HEp-2 cells. Fifty patients with melanoma, 50 with breast cancer, 10 with lung cancer, 354 with systemic sclerosis, 120 with systemic lupus erythematosus and 50 with rheumatoid arthritis were also studied. Recombinant proteins were produced from 5 CENP-F cDNA clones representing amino acids 2192-3317 (p-F1), 5561-7126 (p-F2), 5892-6883 (p-F3), 7538-10,116 (p-F4) and 9242-10,096 (p-F5). The presence of CENP-F antigen was studied in a breast carcinoma cell line, cryosections of breast carcinoma, normal breast tissue and tonsils.
Twenty-two of 36 patients with CENP-F antibodies had neoplasms; breast (9/22) and lung (5/22) cancer were the most common diagnoses. Thirty-three sera were available for further study; when tested for reactivity to the recombinant peptides, the sera of 21 of 21 patients with neoplasms and 5 of 12 patients with other diseases bound the C-terminal p-F4 peptide. When the terminal third of the p-F4 peptide (p-F5) was studied, a significant difference in pattern of reactivity was not detected. By comparison, the frequency of reactivity with peptides representing other domains of CENP-F was less than that with p-F4 (p-F2 > p-F3 > p-F1). CENP-F autoantibodies were not found in any of the control sera from patients with systemic lupus erythematosus, rheumatoid arthritis or systemic sclerosis or in unselected sera from various malignancies. CENP-F antigens were identified in breast carcinoma tissue but were rarely observed in normal tissues.
A high proportion of individuals with CENP-F antibodies have neoplasia, and there is a bias among their sera for reactivity with determinants in the carboxy terminal domain of CENP-F. CENP-F antigens appear to be highly expressed in malignant tissues.</abstract><cop>Toronto, ON</cop><pub>Canadian Medical Association</pub><pmid>9336656</pmid><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0147-958X |
| ispartof | Clinical and investigative medicine, 1997-10, Vol.20 (5), p.308-319 |
| issn | 0147-958X 1488-2353 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79341151 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Autoantibodies - blood Autoantigens - immunology Biological and medical sciences Breast Neoplasms - immunology Carcinoma, Small Cell - immunology Centromere - immunology Chromosomal Proteins, Non-Histone - immunology Female Fluorescent Antibody Technique, Indirect Humans Immunology Investigative techniques, diagnostic techniques (general aspects) Lung Neoplasms - immunology Male Medical sciences Melanoma - immunology Microfilament Proteins Middle Aged Miscellaneous. Technology Neoplasms - immunology Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Proteins Retrospective Studies Rheumatic Diseases - immunology |
| title | High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A48%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20frequency%20of%20neoplasia%20in%20patients%20with%20autoantibodies%20to%20centromere%20protein%20CENP-F&rft.jtitle=Clinical%20and%20investigative%20medicine&rft.au=RATTNER,%20J.%20B&rft.date=1997-10-01&rft.volume=20&rft.issue=5&rft.spage=308&rft.epage=319&rft.pages=308-319&rft.issn=0147-958X&rft.eissn=1488-2353&rft.coden=CNVMDL&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E19472186%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196425333&rft_id=info:pmid/9336656&rfr_iscdi=true |